ACM
AVXL icon

ACT Capital Management’s Anavex Life Sciences AVXL Stock Holding History

ACT Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-33,500
Closed -$581K – 87
2021
Q4 		$581K Sell
33,500
-37,000
-52% -$703K 0.42% 43
2021
Q3 		$1.26M Buy
+70,500
New +$1.4M 0.66% 33

Other funds holding AVXL

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

ACT Capital Management's AVXL Position: Q1 2022 in Review

ACT Capital Management sold out of Anavex Life Sciences (AVXL) in Q1 2022, closing a stake of 33,500 shares — an estimated $581K sold.

ACT Capital Management first reported a position in AVXL in Q3 2021 and held it in 2 quarters. The position peaked at $1.26M in Q3 2021. 139 funds tracked by Wall St. Rank hold AVXL as of Q1 2022.

  • ACT Capital Management reported no remaining Anavex Life Sciences position as of Q1 2022 after selling out during the quarter.
  • ACT Capital Management sold 33,500 Anavex Life Sciences shares in Q1 2022, an estimated $581K.
  • ACT Capital Management first reported a position in Anavex Life Sciences in Q3 2021 and held it in 2 quarters.
  • ACT Capital Management's Anavex Life Sciences position peaked at $1.26M in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2022.

Based on ACT Capital Management's 13F filing for Q1 2022, filed 11 May 2022.